These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
668 related articles for article (PubMed ID: 9412794)
1. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794 [TBL] [Abstract][Full Text] [Related]
2. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. Miyake H; Hara I; Eto H BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202 [TBL] [Abstract][Full Text] [Related]
4. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332 [TBL] [Abstract][Full Text] [Related]
5. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938 [TBL] [Abstract][Full Text] [Related]
6. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach. Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681 [TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K; Lehnert M; Stettner H; Hubmer G Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791 [TBL] [Abstract][Full Text] [Related]
8. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Herrada J; Dieringer P; Logothetis CJ J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675 [TBL] [Abstract][Full Text] [Related]
9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
10. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L; Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109 [TBL] [Abstract][Full Text] [Related]
11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M; Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491 [TBL] [Abstract][Full Text] [Related]
13. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? Perachino M; Cavalli V; Bravi F BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358 [TBL] [Abstract][Full Text] [Related]
14. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428 [TBL] [Abstract][Full Text] [Related]
15. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308 [TBL] [Abstract][Full Text] [Related]
16. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. Cherrier MM; Rose AL; Higano C J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781 [TBL] [Abstract][Full Text] [Related]
17. Predictors of androgen independence in metastatic prostate cancer. Sim HG; Lau WK; Cheng CW BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610 [TBL] [Abstract][Full Text] [Related]
18. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528 [TBL] [Abstract][Full Text] [Related]
19. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685 [TBL] [Abstract][Full Text] [Related]
20. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]